Healthcare | February 28, 2023
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Subscribe To Our Newsletter & Stay Updated
